Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance.

Abstract

The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors will respond to cetuximab, and even in tumors that regress with treatment, acquired resistance occurs in the majority of cases. Though a number of mechanisms of acquired resistance to cetuximab have been identified in preclinical studies, no therapies targeting these resistance pathways have yet been effectively translated into the clinic. To address this unmet need, we examined the role of the cytokine interleukin 6 (IL-6) in acquired cetuximab resistance in preclinical models of HNSCC. We found that IL-6 secretion was increased in PE/CA-PJ49 cells that had acquired resistance to cetuximab compared to the parental cells from which they were derived. However, addition of exogenous IL-6 to parental cells did not promote cetuximab resistance, and inhibition of the IL-6 pathway did not restore cetuximab sensitivity in the cetuximab-resistant cells. Further examination of the IL-6 pathway revealed that expression of IL6R, which encodes a component of the IL-6 receptor, was decreased in cetuximab-resistant cells compared to parental cells, and that treatment of the cetuximab-resistant cells with exogenous IL-6 did not induce phosphorylation of signal transducer and activator of transcription 3, suggesting that the IL-6 pathway was functionally impaired in the cetuximab-resistant cells. These findings demonstrate that, even if IL-6 is increased in the context of cetuximab resistance, it is not necessarily required for maintenance of the resistant phenotype, and that targeting the IL-6 pathway may not restore sensitivity to cetuximab in cetuximab-refractory HNSCC.

• Authors: Rachel A O'Keefe, Neil E Bhola, David S Lee, Daniel E Johnson, Jennifer R Grandis
• Journal: PloS one (PLoS One) Vol. 15 Issue 1 Pg. e0227261 ( 2020) ISSN: 1932-6203 [Electronic] United States
• PMID: 31914141 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antibodies, Monoclonal, Humanized
• CBLC137
• Carbazoles
• IL6 protein, human
• IL6R protein, human
• Interleukin-6
• RNA, Small Interfering
• Receptors, Interleukin-6
• Recombinant Proteins
• STAT3 Transcription Factor
• STAT3 protein, human
• EGFR protein, human
• ErbB Receptors
• tocilizumab
• Cetuximab
• Cisplatin

Topics

• Antibodies, Monoclonal, Humanized (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (pharmacology, therapeutic use)
• Carbazoles
• Cell Line, Tumor
• Cetuximab (pharmacology, therapeutic use)
• Cisplatin (pharmacology, therapeutic use)
• Drug Resistance, Neoplasm (drug effects, immunology)
• Drug Screening Assays, Antitumor
• ErbB Receptors (antagonists & inhibitors)
• Gene Knockdown Techniques
• Head and Neck Neoplasms (drug therapy, immunology, pathology)
• Humans
• Interleukin-6 (genetics, immunology, metabolism)
• Phosphorylation
• RNA, Small Interfering (metabolism)
• Receptors, Interleukin-6 (antagonists & inhibitors, genetics, immunology, metabolism)
• Recombinant Proteins (immunology)
• STAT3 Transcription Factor (metabolism)
• Signal Transduction (drug effects, genetics, immunology)
• Squamous Cell Carcinoma of Head and Neck (drug therapy, immunology, pathology)